Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2023-02-10 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
关于使用募集资金置换预先投入募投项目及已支付发行费用的自筹资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the use of raised funds to replace previously invested self-raised funds in investment projects and issuance expenses. It includes details about the fundraising, approvals from the board and supervisory committee, independent director opinions, and auditor verification. The document is a formal disclosure about the company's capital management and use of proceeds from a non-public stock issuance. It does not contain full financial statements or comprehensive financial performance data, nor is it a transcript, presentation, or report publication announcement. The content focuses on capital usage and financing activities related to the company's fundraising and capital structure. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is over 5,000 characters and contains substantive information about the capital usage, not just a brief announcement or certification, so it is not RPA or RNS. Hence, the classification is CAP with high confidence.
2023-02-10 Chinese
关于使用闲置募集资金进行现金管理的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by a company regarding the use of idle raised funds for cash management. It details the approval by the board and supervisory committee, the investment purpose, types of investments, risk control measures, and related opinions from independent directors and the sponsoring institution. The document does not contain financial statements or detailed financial data but rather describes a corporate decision and regulatory compliance related to the use of funds. It is a regulatory announcement about financing activities but not a full capital or financing update report with financial data. Given the content and length (under 5,000 characters), it fits best as a Regulatory Filing (RNS) rather than a Capital/Financing Update (CAP) or other categories.
2023-02-10 Chinese
独立董事对相关事项发表的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion statement from independent directors regarding various corporate matters such as termination of a stock incentive plan, changes in project implementation entities, use of raised funds, and cash management of idle raised funds. It references compliance with regulatory rules and internal company procedures but does not contain financial statements or detailed financial results. The document is a formal opinion related to corporate governance and regulatory compliance rather than a full financial report or announcement of voting results. It is not a report publication announcement as it contains substantive independent director opinions. Therefore, it fits best under Regulatory Filings (RNS) as a formal regulatory compliance document that does not fit other specific categories.
2023-02-10 Chinese
关于复方氨基酸注射液（18AA-IX）通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a pharmaceutical product's consistency evaluation by the National Medical Products Administration of China. It includes details about the drug, regulatory approval, and risk warnings. The document is short (1339 characters) and serves as a formal announcement of regulatory approval rather than a detailed financial or management report. It does not contain financial statements, management changes, or meeting materials. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-02-07 Chinese
海思科医药集团股份有限公司2020年度非公开发行A股股票发行情况暨上市公告书
Capital/Financing Update Classification · 95% confidence The document is titled as a "2020年度非公开发行A股股票发行情况暨上市公告书" which translates to "2020 Non-public Issuance of A Shares Stock Issuance and Listing Announcement". It details the issuance quantity, pricing, subscription, allotment, and listing arrangements of new shares. It includes information about the issuance process, approval by regulatory bodies (China Securities Regulatory Commission), subscription details, allotment to investors, and lock-up periods. The document is comprehensive and contains detailed financial and procedural information about a capital raising event through a non-public stock issuance. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes. It is not an announcement of a report publication but the actual detailed issuance report. Therefore, the correct classification is CAP with high confidence.
2023-02-05 Chinese
关于董事、监事和高级管理人员持股情况变动的报告
Major Shareholding Notification Classification · 95% confidence The document is a report about changes in shareholding by the company's directors, supervisors, and senior management. It details the non-public issuance of shares, the subscription details, and explicitly states that the shareholding quantities of directors, supervisors, and senior management did not change, but their shareholding ratios changed due to the issuance. This matches the definition of a Major Shareholding Notification, which involves notification of changes in significant share ownership levels or holdings by key insiders. The document is not an earnings release, annual report, or any other financial report type. It is specifically about shareholding changes by insiders, so the correct classification is Major Shareholding Notification (MRQ). The document length is short but contains detailed shareholding data, so it is not a mere announcement or certification. Confidence is high.
2023-02-05 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.